NASDAQ:MBIO Mustang Bio - MBIO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.66 -0.02 (-2.95%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.64▼$0.6850-Day Range$0.32▼$0.7252-Week Range$0.32▼$1.20Volume286,746 shsAverage Volume664,072 shsMarket Capitalization$69.91 millionP/E RatioN/ADividend YieldN/APrice Target$4.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Mustang Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside620.7% Upside$4.75 Price TargetShort InterestHealthy0.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.75) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector354th out of 1,053 stocksPharmaceutical Preparations Industry169th out of 519 stocks 3.5 Analyst's Opinion Consensus RatingMustang Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.75, Mustang Bio has a forecasted upside of 620.7% from its current price of $0.66.Amount of Analyst CoverageMustang Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.39% of the float of Mustang Bio has been sold short.Short Interest Ratio / Days to CoverMustang Bio has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mustang Bio has recently decreased by 23.63%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMustang Bio does not currently pay a dividend.Dividend GrowthMustang Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MBIO. Previous Next 3.6 News and Social Media Coverage News SentimentMustang Bio has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mustang Bio this week, compared to 0 articles on an average week.Search InterestOnly 6 people have searched for MBIO on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows4 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mustang Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Mustang Bio is held by insiders.Percentage Held by InstitutionsOnly 13.66% of the stock of Mustang Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mustang Bio are expected to decrease in the coming year, from ($0.75) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mustang Bio is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mustang Bio is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMustang Bio has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mustang Bio (NASDAQ:MBIO) StockMustang Bio, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.Read More Receive MBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address MBIO Stock News HeadlinesDecember 19, 2022 | finance.yahoo.comMustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated MilestonesNovember 15, 2022 | finanznachrichten.deMustang Bio, Inc.: Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.October 6, 2022 | baystreet.caMustang Bio Unchanged on Test ResultsOctober 6, 2022 | finance.yahoo.comMustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaSeptember 23, 2022 | seekingalpha.comMustang Bio: This Horse May Gallop StillSeptember 8, 2022 | finance.yahoo.comMustang Bio to Participate in Upcoming September 2022 Investor ConferencesSeptember 2, 2022 | finance.yahoo.comHere's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom FishingFebruary 2, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.August 19, 2022 | seekingalpha.comMustang Bio (MBIO) Corporate Presentation - SlideshowAugust 12, 2022 | benzinga.comRecap: Mustang Bio Q2 EarningsJuly 23, 2022 | nasdaq.comMustang Bio, Inc. (NASDAQ:MBIO) Shares Could Be 50% Below Their Intrinsic Value EstimateJuly 17, 2022 | finance.yahoo.comMustang Bio, Inc. (NASDAQ:MBIO) insider upped their holding by 9.9% earlier this yearJuly 15, 2022 | uk.finance.yahoo.comMustang Bio, Inc. (MBIO)June 22, 2022 | msn.comMustang Bio Shares Gain As FDA Grants Orphan Drug Status To Waldenstrom DrugJune 22, 2022 | seekingalpha.comMustang Bio CAR T cell therapy for rare blood cancer gets FDA orphan drug statusJune 22, 2022 | marketwatch.comMustang Bio Gets Orphan Drug Designation for MB-106 Lymphoma TreatmentJune 22, 2022 | finance.yahoo.comMustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom MacroglobulinemiaJune 13, 2022 | seekingalpha.comMustang Bio updates interim data for blood cancer candidateJune 13, 2022 | finance.yahoo.comMustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T TherapyMay 19, 2022 | seekingalpha.comMustang announces positive data from gene therapy trial to treat X-linked immunodeficiencyMay 19, 2022 | finance.yahoo.comMustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In ImmunodeficiencyMay 12, 2022 | finance.yahoo.comMustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsMay 12, 2022 | finance.yahoo.comMustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid CongressMay 4, 2022 | seekingalpha.comMustang Bio: The Market Is Missing This OpportunityMay 3, 2022 | finance.yahoo.comMustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual MeetingApril 25, 2022 | finance.yahoo.comMustang Bio's CAR T Cell Therapy Shows Favorable Safety Profile, Response Rates In Blood Cancer PatientsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address MBIO Company Calendar Last Earnings11/14/2022Today2/02/2023Next Earnings (Estimated)3/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MBIO CUSIPN/A CIK1680048 Webwww.mustangbio.com Phone(781) 652-4500FaxN/AEmployees102Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.75 High Stock Price Forecast$7.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+620.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.56% Return on Assets-63.25% Debt Debt-to-Equity Ratio0.42 Current Ratio6.97 Quick Ratio6.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.19 per share Price / Book0.55Miscellaneous Outstanding Shares106,070,000Free Float103,946,000Market Cap$69.91 million OptionableOptionable Beta1.87 Key ExecutivesManuel LitchmanPresident, Chief Executive Officer & DirectorEliot M. LurierChief Financial OfficerKnut NissChief Technology OfficerBruce DezubeSenior Vice President & Head-Clinical DevelopmentSusan E. WardVice President-Clinical OperationsKey CompetitorsHCW BiologicsNASDAQ:HCWBGalera TherapeuticsNASDAQ:GRTXGenprexNASDAQ:GNPXSpruce BiosciencesNASDAQ:SPRBAnebulo PharmaceuticalsNASDAQ:ANEBView All CompetitorsInsiders & InstitutionsSpotlight Asset Group Inc.Bought 305,312 shares on 11/18/2022Ownership: 0.288%Vanguard Group Inc.Bought 482,361 shares on 11/15/2022Ownership: 2.514%BlackRock Inc.Sold 33,149 shares on 11/15/2022Ownership: 2.102%Two Sigma Advisers LPSold 150,300 shares on 11/15/2022Ownership: 0.191%Two Sigma Investments LPSold 78,382 shares on 11/15/2022Ownership: 0.129%View All Institutional Transactions MBIO Stock - Frequently Asked Questions Should I buy or sell Mustang Bio stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBIO shares. View MBIO analyst ratings or view top-rated stocks. What is Mustang Bio's stock price forecast for 2023? 3 analysts have issued twelve-month price targets for Mustang Bio's stock. Their MBIO share price forecasts range from $4.00 to $7.00. On average, they expect the company's stock price to reach $4.75 in the next year. This suggests a possible upside of 620.7% from the stock's current price. View analysts price targets for MBIO or view top-rated stocks among Wall Street analysts. How have MBIO shares performed in 2023? Mustang Bio's stock was trading at $0.3949 at the beginning of the year. Since then, MBIO stock has increased by 66.9% and is now trading at $0.6591. View the best growth stocks for 2023 here. Are investors shorting Mustang Bio? Mustang Bio saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 319,000 shares, a decrease of 23.6% from the December 31st total of 417,700 shares. Based on an average daily volume of 500,800 shares, the short-interest ratio is currently 0.6 days. Approximately 0.4% of the company's shares are short sold. View Mustang Bio's Short Interest. When is Mustang Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023. View our MBIO earnings forecast. How were Mustang Bio's earnings last quarter? Mustang Bio, Inc. (NASDAQ:MBIO) posted its earnings results on Monday, November, 14th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. What other stocks do shareholders of Mustang Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Fortress Biotech (FBIO), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Aytu BioPharma (AYTU) and Kadmon (KDMN). What is Mustang Bio's stock symbol? Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO." Who are Mustang Bio's major shareholders? Mustang Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Achenbach, Lindsay A Md Rosenwald and Manuel Md Litchman. View institutional ownership trends. How do I buy shares of Mustang Bio? Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mustang Bio's stock price today? One share of MBIO stock can currently be purchased for approximately $0.66. How much money does Mustang Bio make? Mustang Bio (NASDAQ:MBIO) has a market capitalization of $69.91 million. The company earns $-66,370,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. How many employees does Mustang Bio have? The company employs 102 workers across the globe. How can I contact Mustang Bio? Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The official website for the company is www.mustangbio.com. The company can be reached via phone at (781) 652-4500 or via email at ir@mustangbio.com. This page (NASDAQ:MBIO) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.